Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

Ildiko Lingvay, Stewart Harris, Elmar Jaeckel, Keval Chandarana, Mattis F. Ranthe, Esteban Jódar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; <30, ≥30 to <35 and ≥35kg/m2) and fasting plasma glucose (FPG; <7.2 and ≥7.2mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%-2.5%), FPG (1.5%-1.9%) and BMI categories (1.8%-1.9%), with significantly greater reductions compared with IGlar U100. For all HbA1c, FPG and BMI categories, IDegLira resulted in weight loss and IGlar U100 in weight gain; hypoglycaemia rates were lower for IDegLira vs IGlar U100. More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%-87% vs 31%-66%), FPG (71%-74% vs 40%-51%) and BMI categories (71%-73% vs 40%-54%). IDegLira improved glycaemic control and induced weight loss in patients with T2D previously uncontrolled on basal insulin, across the categories of baseline HbA1c, FPG or BMI that were tested.

Original languageEnglish (US)
JournalDiabetes, Obesity and Metabolism
DOIs
StateAccepted/In press - 2017

Fingerprint

Body Mass Index
Type 2 Diabetes Mellitus
Weight Loss
Insulin
Glycosylated Hemoglobin A
Hypoglycemia
Weight Gain
Liraglutide
insulin degludec
Fasting
Insulin Glargine
Glucose

Keywords

  • IDegLira
  • Body mass index
  • Clinical trial
  • Insulin therapy
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. / Lingvay, Ildiko; Harris, Stewart; Jaeckel, Elmar; Chandarana, Keval; Ranthe, Mattis F.; Jódar, Esteban.

In: Diabetes, Obesity and Metabolism, 2017.

Research output: Contribution to journalArticle

@article{62be43fd8e2b4b7986a009effc8880d8,
title = "Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial",
abstract = "This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5{\%}, >7.5{\%} to ≤8.5{\%} and >8.5{\%}), body mass index (BMI; <30, ≥30 to <35 and ≥35kg/m2) and fasting plasma glucose (FPG; <7.2 and ≥7.2mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0{\%}-2.5{\%}), FPG (1.5{\%}-1.9{\%}) and BMI categories (1.8{\%}-1.9{\%}), with significantly greater reductions compared with IGlar U100. For all HbA1c, FPG and BMI categories, IDegLira resulted in weight loss and IGlar U100 in weight gain; hypoglycaemia rates were lower for IDegLira vs IGlar U100. More patients achieved HbA1c <7{\%} with IDegLira than IGlar U100 across all HbA1c (59{\%}-87{\%} vs 31{\%}-66{\%}), FPG (71{\%}-74{\%} vs 40{\%}-51{\%}) and BMI categories (71{\%}-73{\%} vs 40{\%}-54{\%}). IDegLira improved glycaemic control and induced weight loss in patients with T2D previously uncontrolled on basal insulin, across the categories of baseline HbA1c, FPG or BMI that were tested.",
keywords = "IDegLira, Body mass index, Clinical trial, Insulin therapy, Type 2 diabetes",
author = "Ildiko Lingvay and Stewart Harris and Elmar Jaeckel and Keval Chandarana and Ranthe, {Mattis F.} and Esteban J{\'o}dar",
year = "2017",
doi = "10.1111/dom.13043",
language = "English (US)",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

AU - Lingvay, Ildiko

AU - Harris, Stewart

AU - Jaeckel, Elmar

AU - Chandarana, Keval

AU - Ranthe, Mattis F.

AU - Jódar, Esteban

PY - 2017

Y1 - 2017

N2 - This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; <30, ≥30 to <35 and ≥35kg/m2) and fasting plasma glucose (FPG; <7.2 and ≥7.2mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%-2.5%), FPG (1.5%-1.9%) and BMI categories (1.8%-1.9%), with significantly greater reductions compared with IGlar U100. For all HbA1c, FPG and BMI categories, IDegLira resulted in weight loss and IGlar U100 in weight gain; hypoglycaemia rates were lower for IDegLira vs IGlar U100. More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%-87% vs 31%-66%), FPG (71%-74% vs 40%-51%) and BMI categories (71%-73% vs 40%-54%). IDegLira improved glycaemic control and induced weight loss in patients with T2D previously uncontrolled on basal insulin, across the categories of baseline HbA1c, FPG or BMI that were tested.

AB - This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; <30, ≥30 to <35 and ≥35kg/m2) and fasting plasma glucose (FPG; <7.2 and ≥7.2mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%-2.5%), FPG (1.5%-1.9%) and BMI categories (1.8%-1.9%), with significantly greater reductions compared with IGlar U100. For all HbA1c, FPG and BMI categories, IDegLira resulted in weight loss and IGlar U100 in weight gain; hypoglycaemia rates were lower for IDegLira vs IGlar U100. More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%-87% vs 31%-66%), FPG (71%-74% vs 40%-51%) and BMI categories (71%-73% vs 40%-54%). IDegLira improved glycaemic control and induced weight loss in patients with T2D previously uncontrolled on basal insulin, across the categories of baseline HbA1c, FPG or BMI that were tested.

KW - IDegLira

KW - Body mass index

KW - Clinical trial

KW - Insulin therapy

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85026461534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026461534&partnerID=8YFLogxK

U2 - 10.1111/dom.13043

DO - 10.1111/dom.13043

M3 - Article

C2 - 28643425

AN - SCOPUS:85026461534

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

ER -